Eight months after Visiox Pharmaceuticals was all set to go public via a special purpose acquisition company (SPAC) deal, the company has been snapped up by fellow eye-focused biotech Ocuvex Therapeutics instead. Visiox said the newly combined entity will be “an emerging leader in the eye care sector with an exciting portfolio of ophthalmic medicines.” One of these meds will be Omlonti, an approved omidenepag isopropyl ophthalmic solution licensed by Visiox from Santen Pharmaceutical a year ago. The prostaglandin E2 receptor agonist is indicated for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension.
Read the full article: After SPAC Deal Fell Flat, Visiox Acquired by Fellow Eye-Focused Biotech //
Source: https://www.fiercepharma.com/pharma/after-spac-deal-fell-flat-visiox-acquired-another-eye-focused-biotech